AVANIR to Present at the Needham Life Sciences Conference
ALISO VIEJO, Calif., June 4, 2009 - AVANIR Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced that the Company will present at the 8th Annual Needham Life Sciences Conference on Thursday, June 11th at 9:00 a.m. Eastern time (6:00 a.m. Pacific time) at the New York Palace Hotel in New York City. The Needham Life Sciences Conference is a leading industry event attracting over 100 of the health care industry's most prestigious companies. The conference provides participating companies with the opportunity to present to institutional investors and industry experts.
A live audio webcast of the presentation will be available by visiting AVANIR's website at www.avanir.com. To listen to the live presentation, please go to AVANIR's website prior to the start of the presentation to register, download and install the necessary audio software. An archive of the presentation at the Needham Life Sciences Conference will be available on the Company's website for 30 days.
AVANIR Pharmaceuticals, Inc. is focused on acquiring, developing, and commercializing novel therapeutic products for the treatment of chronic diseases. AVANIR's products and product candidates address therapeutic markets that include the central nervous system, inflammation, and infectious diseases. AVANIR's lead product candidate, Zenvia™, is being developed for the treatment of pseudobulbar affect (PBA) and diabetic peripheral neuropathic (DPN) pain. AVANIR has licensed its MIF inhibitor program to Novartis International Pharmaceuticals Ltd. and has sold its anthrax monoclonal antibody program to Emergent BioSolutions. The Company's first commercialized product, Abreva®, is marketed in North America by GlaxoSmithKline Consumer Healthcare and is the leading over-the-counter product for the treatment of cold sores. Further information about AVANIR can be found at www.avanir.com and further information about PBA can be found at www.PBAinfo.org.
To be included on AVANIR's e-mail alert list; click on the link below or visit AVANIR's website:
AVANIR Investor Contacts
Jun 04, 2009